Piperacillin/ Tazobactam is indicated in the treatment of serious bacterial infections caused by susceptible strains of β-lactamase producing organisms in the conditions listed below:
•Lower respiratory tract infections
•Urinary tract infections (complicated and uncomplicated)
•Intra-abdominal infections
•Skin and skin structure infections
•Bacterial septicaemia
•Gynaecological infections
Children under the age of 12
In hospitalised children aged 2 to 12 years, Piperacillin/ Tazobactam is indicated for the treatment of serious intra-abdominal infections. It has not been evaluated in this indication for paediatric patients below the age of 2 years. While Piperacillin/ Tazobactam is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and β-lactamase producing, piperacillin-resistant organisms. Appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to Piperacillin/ Tazobactam. Therapy with Piperacillin/ Tazobactam, however, may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the β-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued. In serious infections, presumptive therapy with Piperacillin/Tazobactam may be initiated before susceptibility test results are available. Combination therapy with Piperacillin/Tazobactam and aminoglycosides may be used in the treatment of serious infections caused by Pseudomonas aeruginosa. Both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted. |
Wed 14 Oct 2026
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.